Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval

MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court